Varma Mutual Pension Insurance Co Has $24.48 Million Holdings in Pfizer Inc. $PFE

Varma Mutual Pension Insurance Co raised its holdings in Pfizer Inc. (NYSE:PFE) by 9.4% in the third quarter, Holdings Channel reports. The fund owned 960,563 shares of the biopharmaceutical company’s stock after acquiring an additional 82,500 shares during the period. Varma Mutual Pension Insurance Co’s holdings in Pfizer were worth $24,475,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of PFE. Curio Wealth LLC increased its stake in Pfizer by 36,600.0% during the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 1,098 shares in the last quarter. Harbor Asset Planning Inc. bought a new position in Pfizer in the second quarter valued at approximately $29,000. Grey Fox Wealth Advisors LLC acquired a new position in shares of Pfizer in the third quarter valued at approximately $29,000. Howard Hughes Medical Institute bought a new stake in shares of Pfizer during the second quarter worth $30,000. Finally, Darwin Wealth Management LLC acquired a new stake in shares of Pfizer during the second quarter worth $32,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q4 earnings beat and an upbeat outlook plus unusual call‑option activity suggest investors are bullish on near‑term upside. Pfizer Reports Strong Earnings Outlook
• Positive Sentiment: Post‑earnings bullish analysis argues the pullback could be a buying opportunity as fundamentals and buybacks support valuation. Pfizer: A Great Opportunity Post Earnings
• Positive Sentiment: Company returned $9.8B to shareholders in 2025 (buybacks/dividends), which supports per‑share metrics and investor demand. Pfizer Closes 2025 on Solid Note
• Positive Sentiment: Pfizer will collect $29M in an SEC‑related settlement, a small one‑time cash benefit and removal of legal overhang. Pfizer to collect $29 million
• Neutral Sentiment: Coverage pieces and screeners note Pfizer is trending and yields are attracting income investors; this supports interest but may cap upside if growth doubts persist. PFE Is a Trending Stock
• Neutral Sentiment: Analyses flag that pipeline progress and partnerships are real but must overcome a depressed valuation — potential upside if clinical wins arrive, but timing is uncertain. Pipeline Progress and Partnerships Tested
• Negative Sentiment: Daiwa downgraded PFE from outperform to neutral and set a $27 price target, signaling limited near‑term upside from their view. Daiwa Downgrade via Finviz
• Negative Sentiment: Commentary raises the risk Pfizer could be a value trap given fading COVID revenue and a looming 2026–2030 patent cliff; pipeline and M&A must offset lost blockbuster sales. Can New Drugs Offset Patent Cliff?
• Negative Sentiment: Opinion pieces question whether PFE is a value trap despite yields — these narratives can pressure sentiment if additional negative data or downgrades appear. Is Pfizer Stock Now A Value Trap?

Analysts Set New Price Targets

PFE has been the topic of several research reports. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research report on Wednesday, December 17th. Scotiabank started coverage on Pfizer in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 price target on the stock. Wolfe Research set a $24.00 price objective on Pfizer and gave the stock an “underperform” rating in a report on Wednesday, December 17th. Bank of America dropped their target price on Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a research report on Monday, December 15th. Finally, TD Cowen reaffirmed a “hold” rating on shares of Pfizer in a research report on Tuesday, December 30th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, thirteen have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Pfizer presently has an average rating of “Hold” and an average price target of $28.00.

Pfizer Stock Performance

PFE opened at $27.74 on Thursday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. The business’s 50-day simple moving average is $25.74 and its 200 day simple moving average is $25.15. The firm has a market capitalization of $157.70 billion, a PE ratio of 20.39 and a beta of 0.47. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $27.94.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a return on equity of 20.25% and a net margin of 12.42%.The company had revenue of $17.56 billion for the quarter, compared to analysts’ expectations of $16.93 billion. During the same quarter in the prior year, the business posted $0.63 EPS. The business’s revenue was down 1.2% compared to the same quarter last year. As a group, sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, January 23rd. This represents a $1.72 annualized dividend and a dividend yield of 6.2%. Pfizer’s payout ratio is currently 126.47%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.